Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) have received an average rating of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $15.40.

A number of equities research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th. Wells Fargo & Company increased their price objective on Relay Therapeutics from $13.00 to $15.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. Finally, Oppenheimer raised Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price objective on the stock in a report on Monday, January 26th.

Relay Therapeutics Price Performance

Shares of NASDAQ:RLAY opened at $10.80 on Thursday. The company’s fifty day moving average price is $8.63 and its 200-day moving average price is $7.11. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -6.67 and a beta of 1.55. Relay Therapeutics has a one year low of $1.77 and a one year high of $11.43.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. The company had revenue of $7.00 million for the quarter, compared to the consensus estimate of $4.34 million. As a group, equities research analysts expect that Relay Therapeutics will post -2.55 EPS for the current year.

Insider Buying and Selling at Relay Therapeutics

In other news, insider Donald A. Bergstrom sold 18,895 shares of the company’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total value of $143,979.90. Following the completion of the sale, the insider owned 422,733 shares of the company’s stock, valued at approximately $3,221,225.46. This represents a 4.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sanjiv Patel sold 43,168 shares of the stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $7.82, for a total transaction of $337,573.76. Following the transaction, the chief executive officer directly owned 661,041 shares in the company, valued at approximately $5,169,340.62. This represents a 6.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 93,302 shares of company stock valued at $724,355 over the last ninety days. Insiders own 4.87% of the company’s stock.

Institutional Trading of Relay Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Torren Management LLC bought a new position in shares of Relay Therapeutics during the fourth quarter valued at about $30,000. Quinn Opportunity Partners LLC bought a new stake in shares of Relay Therapeutics in the 2nd quarter valued at about $35,000. Smartleaf Asset Management LLC boosted its holdings in Relay Therapeutics by 288.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after acquiring an additional 3,287 shares during the period. Quadrant Capital Group LLC boosted its holdings in Relay Therapeutics by 245.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 11,791 shares of the company’s stock valued at $41,000 after acquiring an additional 8,374 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new position in Relay Therapeutics during the 4th quarter worth approximately $46,000. 96.98% of the stock is currently owned by hedge funds and other institutional investors.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.